

# Cyclosporin A (9E10): sc-80997

## BACKGROUND

Cyclosporin A, also known as CsA, is a compound that is isolated from the fungus *Tolypocladium inflatum*. Discovery of Cyclosporin A in 1971 marked the beginning of a new era in immunopharmacology. Cyclosporin A was the first immunosuppressive drug that enabled selective immunoregulation of T cells without excessive toxicity. Cyclosporin A is widely used in organ transplant surgery to reduce the risk of organ rejection. Specifically, Cyclosporin A blocks the activity of calcineurin, thus preventing the transcription of IL-2 and reducing the activity of the immune system. In addition, Cyclosporin A inhibits the opening of permeability-transition pores within the mitochondrion, allowing it to function as a neuroprotective agent that can reduce the amount of damage associated with head trauma and neurodegenerative diseases.

## REFERENCES

- Opelz, G. and Döhler, B. 2001. Cyclosporine and long-term kidney graft survival. *Transplantation* 72: 1267-1273.
- Ma, W., Mishra, S., Gee, K., Mishra, J.P., Nandan, D., Reiner, N.E., Angel, J.B. and Kumar, A. 2007. Cyclosporin A and FK-506 inhibit IL-12p40 production through the calmodulin/calmodulin-dependent protein kinase-activated phosphoinositide 3-kinase in lipopolysaccharide-stimulated human monocytic cells. *J. Biol. Chem.* 282: 13351-13362.
- Unal, M. and Yücel, Y. 2008. Evaluation of topical Cyclosporine A 0.05% for prevention of rejection in high-risk corneal grafts. *Br. J. Ophthalmol.* 92: 1411-1414.
- Taniai, N., Akimaru, K., Ishikawa, Y., Kanada, T., Kakinuma, D., Mizuguchi, Y., Mamada, Y., Yoshida, H. and Tajiri, T. 2008. Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation. *J. Nippon Med. Sch.* 75: 187-191.
- Piot, C., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., Elbelghiti, R., Cung, T.T., Bonnefoy, E., Angoulvant, D., Macia, C., Raczka, F., Sportouch, C., Gahide, G., Finet, G., Andre-Fouët, X., Revel, D., Kirkorian, G., Monassier, J.P., Derumeaux, G. and Ovize, M. 2008. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. *N. Engl. J. Med.* 359: 473-481.
- Chen, T.L., Wang, J.A., Shi, H., Gui, C., Luo, R.H., Xie, X.J., Xiang, M.X., Zhang, X. and Cao, J. 2008. Cyclosporin A pre-incubation attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. *Scand. J. Clin. Lab. Invest.* 15: 1-9.
- Ko, H., Hambly, B.D., Eris, J.M., Levidiotis, V., Wyburn, K., Wu, H., Chadban, S.J. and Yin, J.L. 2008. Dendritic cell derived IL-18 production is inhibited by Rapamycin and sanglifehrin A, but not cyclosporine A. *Transpl. Immunol.* 20: 99-105.
- Acott, P.D., O'Regan, P.A., Lee, S.H. and Crocker, J.F. 2008. *In vitro* effect of Cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. *Transpl. Infect. Dis.* 10: 385-390.
- Trammer, B., Amann, A., Haltner-Ukomadu, E., Tillmanns, S., Keller, M. and Högger, P. 2008. Comparative permeability and diffusion kinetics of Cyclosporine A liposomes and propylene glycol solution from human lung tissue into human blood *ex vivo*. *Eur. J. Pharm. Biopharm.* 70: 758-764.

## SOURCE

Cyclosporin A (9E10) is a mouse monoclonal antibody raised against Cyclosporin A of fungal origin.

## PRODUCT

Each vial contains 200 µg IgG<sub>1</sub> in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

Cyclosporin A (9E10) is recommended for detection of Cyclosporin A by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.